Skip to main content

Agora
Sign in

House bill · H.R. 2821 (119th Congress)

FDA Modernization Act 3.0

U.S. House of Representatives

Latest action Jul 21, 2026

Sponsor: Earl L. "Buddy" Carter (U.S. Representative, GA-1, Republican)

Follow

Following needs an Agora account. You will sign in first, then come back to this page.

From Congress.gov and official rosters. This record was last updated Sep 8, 2026. About our data

Summary

FDA Modernization Act 3.0 This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug. The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications. The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.

Summary from the Congressional Research Service. How we handle summaries

Where it stands

Passed one of the two chambers; it still needs the other.

  1. Introduced
  2. In committee
  3. Up for a vote
  4. Passed one chamber
  5. Passed
  6. Enacted

Committee

House Committee on Energy and Commerce · U.S. House of Representatives

Your position on this bill

Choose the position closest to yours. You'll sign in or create an account to save it.

Sign in or create an account to give your position

Cosponsors

41

Cosponsors listed on Congress.gov, shown A to Z.

  • Democratic21
  • Republican20

This bill has cosponsors from more than one party.

Shown in neutral colors by design; Agora is non-partisan.

Show the full list (41 names)

Related bills

As identified by Congress.gov.

Full history

  1. Jul 21, 2026

    Sent to the executive

    Received in the Senate.

    U.S. Senate

  2. Jul 20, 2026

    Considered Under Suspension of the rules. (consideration: cr H4639-4640)

    Considered under suspension of the rules. (consideration: CR H4639-4640)

  3. Jul 20, 2026

    Considered Under Suspension of the rules. (consideration: cr H4639-4640)

    Considered under suspension of the rules. (consideration: CR H4639-4640)

  4. Jul 20, 2026

    Considered Under Suspension of the rules. (consideration: cr H4639-4640)

    Considered under suspension of the rules. (consideration: CR H4639-4640)

  5. Jul 20, 2026

    Debate - the House Proceeded With Forty Minutes of Debate on H.R. 2821.

    DEBATE - The House proceeded with forty minutes of debate on H.R. 2821.

    U.S. House of Representatives

Show full history (29 earlier events)
  1. Jul 20, 2026

    Passed a chamber

    Motion to reconsider laid on the table Agreed to without objection.

  2. Jul 20, 2026

    Passed a chamber

    Motion to reconsider laid on the table Agreed to without objection.

  3. Jul 20, 2026

    Passed a chamber

    Motion to reconsider laid on the table Agreed to without objection.

  4. Jul 20, 2026

    Passed a chamber

    Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H4639)

    U.S. House of Representatives

  5. Jun 18, 2026

    Placed on the Union Calendar, Calendar No. 614.

  6. Jun 18, 2026

    Placed on the Union Calendar, Calendar No. 614.

  7. Jun 18, 2026

    Introduced

    Placed on the Union Calendar, Calendar No. 614.

    U.S. House

  8. Jun 18, 2026

    Placed on the Union Calendar, Calendar No. 614.

  9. Jun 18, 2026

    Reported out of committee

    Reported by the Committee on Energy and Commerce. H. Rept. 119-706.

  10. Jun 18, 2026

    Reported out of committee

    Reported by the Committee on Energy and Commerce. H. Rept. 119-706.

  11. Jun 18, 2026

    Reported out of committee

    Reported by the Committee on Energy and Commerce. H. Rept. 119-706.

  12. May 21, 2026

    Committee vote

    Committee Consideration and Mark-up Session Held

  13. May 21, 2026

    Committee vote

    Committee Consideration and Mark-up Session Held

  14. May 21, 2026

    Committee vote

    Committee Consideration and Mark-up Session Held

  15. May 21, 2026

    Reported out of committee

    Ordered to be Reported by the Yeas and Nays: 44 - 0.

  16. May 21, 2026

    Reported out of committee

    Ordered to be Reported by the Yeas and Nays: 44 - 0.

  17. May 21, 2026

    Reported out of committee

    Ordered to be Reported by the Yeas and Nays: 44 - 0.

  18. May 13, 2026

    In committee

    Forwarded by Subcommittee to Full Committee by Voice Vote.

  19. May 13, 2026

    In committee

    Forwarded by Subcommittee to Full Committee by Voice Vote.

  20. May 13, 2026

    In committee

    Forwarded by Subcommittee to Full Committee by Voice Vote.

  21. May 13, 2026

    Committee vote

    Subcommittee Consideration and Mark-up Session Held

  22. May 13, 2026

    Committee vote

    Subcommittee Consideration and Mark-up Session Held

  23. May 13, 2026

    Committee vote

    Subcommittee Consideration and Mark-up Session Held

  24. May 12, 2026

    Introduced

    Introduced in U.S. House

    U.S. House

  25. Apr 10, 2026

    Referred to committee

    Referred to the Subcommittee on Health.

  26. Apr 10, 2026

    Referred to committee

    Referred to the Subcommittee on Health.

  27. Apr 10, 2026

    Referred to committee

    Referred to the Subcommittee on Health.

  28. Apr 10, 2025

    Introduced

    Introduced in House

    U.S. House of Representatives

  29. Apr 10, 2025

    Referred to committee

    Referred to the House Committee on Energy and Commerce.

    U.S. House of Representatives

Read the record